Document Detail


YM-337. Yamanouchi.
MedLine Citation:
PMID:  11892919     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Yamanouchi in collaboration with Protein Design Labs (PDL), is developing YM-337, a humanized antibody (C4G1) for the potential treatment of coronary artery disease, including myocardial infarction, arterial thrombosis and ischemic stroke. The antibody is based on a Yamanouchi murine antibody specific for the glycoprotein (GP) IIb/IIIa receptor found on human platelets 11942421. By June 1999, Yamanouchi was carrying out phase II trials on YM-337 in high-risk percutaneous transluminal coronary angioplasty (PTCA) patients in Europe and the US [326891]. These were ongoing in May 2001 [409092], [411763]. Phase II trials for the potential treatment of ischemic stroke were also underway by this time in Europe and the US [411763]. By 1998, Yamanouchi and PDL had an agreement for the development of a SMART C4G1. Yamanouchi holds exclusize worldwide rights to YM-337 and is responsible for all clinical trials and obtaining regulatory approval. As part of the collaboration, PDL has received milestone payments for humanization of the antibody and is entitled to receive royalties on product sales [274540].
Authors:
S Kamath; G Y Lip
Related Documents :
21970779 - Detection of ophthalmic artery occlusion by visual evoked potential during carotid-opht...
10709069 - Embolic risk of the different stages of carotid bifurcation balloon angioplasty: an exp...
21737559 - Pulmonary fibrosis is associated with an elevated risk of thromboembolic disease.
2418979 - The use of dextran-40 during percutaneous transluminal coronary angioplasty: a report o...
17197719 - Ostial rca intervention: guiding catheter challenges and use of a buddy wire to perform...
8249789 - Quantitative angiography during coronary angioplasty with a single angiographic view: a...
2405049 - Neuroradiological and pathological studies on neonatal aneurysmal dilation of the vein ...
129589 - Surgical treatment of aneurysm of the ascending aorta with aortic insufficiency and mar...
18573409 - Pulsatile pulmonary perfusion during cardiopulmonary bypass reduces the pulmonary infla...
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Current opinion in investigational drugs (London, England : 2000)     Volume:  2     ISSN:  1472-4472     ISO Abbreviation:  Curr Opin Investig Drugs     Publication Date:  2001 Aug 
Date Detail:
Created Date:  2002-03-14     Completed Date:  2002-09-11     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  100965718     Medline TA:  Curr Opin Investig Drugs     Country:  England    
Other Details:
Languages:  eng     Pagination:  1093-6     Citation Subset:  IM    
Affiliation:
City Hospital, The University of Birmingham, University Department of Medicine, UK.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Animals
Antibodies, Monoclonal / adverse effects,  metabolism,  pharmacology,  therapeutic use*
Clinical Trials, Phase I as Topic
Clinical Trials, Phase II as Topic
Humans
Platelet Aggregation Inhibitors / adverse effects,  contraindications,  metabolism,  pharmacology*,  therapeutic use*
Platelet Glycoprotein GPIIb-IIIa Complex / antagonists & inhibitors*
Structure-Activity Relationship
Vascular Diseases / blood,  drug therapy*
Chemical
Reg. No./Substance:
0/Antibodies, Monoclonal; 0/Platelet Aggregation Inhibitors; 0/Platelet Glycoprotein GPIIb-IIIa Complex

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Antiplatelet therapies: platelet GPIIb/IIIa antagonists and beyond.
Next Document:  Darbepoetin alfa. Amgen.